AIDS Treatment News logo      

March 1, 2010

HIV drug that protects a fetus should be avoided for 1 year after childbirth, researchers say

"Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham (UAB).

"A new UAB study found that while nevirapine works well to prevent mother-to-child HIV transmission, a single dose of nevirapine in infected pregnant women can trigger resistance to some forms of the AIDS-drug cocktail known as combination antiretroviral treatment (ART). This nevirapine-induced resistance fades after about 12 months and no longer hinders ART, says UAB Professor of Obstetrics and Gynecology Jeffrey S.A. Stringer, M.D., the study's lead author.

"The findings are published in PLoS Medicine, a journal of the nonprofit Public Library of Science. ...

"The UAB study included 878 infected women in Zambia, Cote d'Ivoire and Thailand. Some were given single-dose nevirapine and others were not; all participants were given ART immediately upon confirmed infection and monitored for one year.

"Nevirapine continues to be the backbone of anti-HIV therapy in the developing world, and its usefulness in preventing mother-to-child transmission is confirmed in the new study, Stringer says."

Read more in EurekAlert!, February 25, 2010.

0 comments: